interleukin-7 + pegylated interferon-alpha + ribavirin

**interleukin-7 + pegylated interferon-alpha + ribavirin** is a triple combination regimen consisting of: - **Interleukin-7 (IL-7):** a recombinant cytokine that promotes proliferation and survival of T cells. IL-7 is being investigated primarily for its immunomodulatory effects, especially in restoring immune function in settings of lymphopenia. - **Pegylated interferon-alpha (pegylated IFN-α):** a cytokine engineered for prolonged half-life by attachment of polyethylene glycol (PEG), commonly used in various forms (e.g., peginterferon alfa-2a or alfa-2b) for hepatitis C and some hematological cancers. It acts primarily through antiviral, antiproliferative, and immunomodulatory mechanisms[1][2][3][4][5]. - **Ribavirin:** an oral antiviral nucleoside analogue, used in combination with interferon for chronic hepatitis C, among other viral infections. Ribavirin inhibits viral replication through multiple mechanisms, including inhibition of viral RNA synthesis and alteration of intracellular nucleotide pools[1][2][3][4][5][6]. This *combination* is not an established commercial product and is not standard of care for any particular indication. However, the dual regimen of pegylated interferon-alpha + ribavirin is well-established for the treatment of chronic hepatitis C infection; the addition of IL-7 would be experimental, potentially aimed at enhancing immune reconstitution or antiviral efficacy, but no major clinical studies using all three together appear in the current literature. Pegylated interferon and ribavirin dual therapy is used for chronic hepatitis C, resulting in improved rates of sustained virological response (SVR) compared to monotherapies, though newer direct-acting antivirals are generally preferred today[2][3][4][5][6]. The mechanisms involve direct antiviral action, immune stimulation, and T cell modulation.